ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Hayat Pharmaceutical Industries Co's annualizedNet Income for the quarter that ended in Mar. 2026 was JOD0.61 Mil.
Hayat Pharmaceutical Industries Co's average Total Assets over the quarter that ended in Mar. 2026 was JOD38.05 Mil. Therefore, Hayat Pharmaceutical Industries Co's annualized ROA % for the quarter that ended in Mar. 2026 was 1.61%.
AMM:HPIC'
s ROA % Range Over the Past 10 Years
Min: 5.15 Med: 11.09 Max: 12.07
Current: 5.15
During the past 13 years, Hayat Pharmaceutical Industries Co's highest ROA % was 12.07%. The lowest was 5.15%. And the median was 11.09%.
AMM:HPIC's ROA % is ranked better than 62.92% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs AMM:HPIC: 5.15
Hayat Pharmaceutical Industries Co (AMM:HPIC) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Hayat Pharmaceutical Industries Co ROA % Related Terms
Hayat Pharmaceutical Industries Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hayat Pharmaceutical Industries Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hayat Pharmaceutical Industries Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hayat Pharmaceutical Industries Co's ROA % distribution charts can be found below:
* The bar in red indicates where Hayat Pharmaceutical Industries Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a ROA % of 1.61% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hayat Pharmaceutical Industries Co and its competitors. This is 85% below median its historical median of 11.09. Over the past decade, Hayat Pharmaceutical Industries Co's ROA % has ranged from 5.15 to 12.07. According to the industry distribution chart, Hayat Pharmaceutical Industries Co ranks #373 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 37.1%.
Is Hayat Pharmaceutical Industries Co's ROA % too high?
Hayat Pharmaceutical Industries Co's current ROA % of 1.61% is 85% below median its 10-year median of 11.09. Over the past 10 years, this metric has ranged from a low of 5.15 to a high of 12.07. The Drug Manufacturers industry median ROA % is 2.69. Hayat Pharmaceutical Industries Co's value of 1.61% is 40% below this industry median. Based on the distribution chart, Hayat Pharmaceutical Industries Co ranks #373 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hayat Pharmaceutical Industries Co ranks #373 out of 1006 companies for ROA %. This puts Hayat Pharmaceutical Industries Co in the upper half of its industry. The industry median ROA % is 2.69. Hayat Pharmaceutical Industries Co's value of 1.61% is 40% below this benchmark. Historically, Hayat Pharmaceutical Industries Co's own ROA % has ranged from 5.15 to 12.07 over the past decade. While the company's 10-year median is 11.09 vs. the industry median of 2.69, Hayat Pharmaceutical Industries Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hayat Pharmaceutical Industries Co's current ROA % of 1.61% is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hayat Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hayat Pharmaceutical Industries Co's current ROA % is 1.61%, which is 85% below median its own 10-year median of 11.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co (AMM:HPIC) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD2.74, compared to a current price of JOD3.13 — trading 14.2% above its estimated fair value. The current ROA % is 1.61%, which is 85% below median its 10-year median of 11.09 and 40% below the Drug Manufacturers industry median of 2.69. Hayat Pharmaceutical Industries Co's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current ROA % is 1.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hayat Pharmaceutical Industries Co (AMM:HPIC) Overvalued in 2026?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co stock appears to be overvalued.
The current stock price of JOD3.13 is trading 14.2% above its estimated GF Value™ of JOD2.74.
GuruFocus considers Hayat Pharmaceutical Industries Co to be Modestly Overvalued.
Key valuation signals for AMM:HPIC:
ROA %: 1.61% (85% below median its 10-year median of 11.09)
GF Value™: JOD2.74 vs. price of JOD3.13 (14.2% above fair value)
Industry Position: 40% below the Drug Manufacturers median (#373 of 1006)
No single metric tells the full story. See the AMM:HPIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hayat Pharmaceutical Industries Co Business Description
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
79GF Score
Get the complete analysis for AMM:HPIC
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:HPIC has been successfully added to your 
